Walleye Capital LLC Purchases Shares of 97,347 Sionna Therapeutics, Inc. $SION

Walleye Capital LLC acquired a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 97,347 shares of the company’s stock, valued at approximately $4,282,000.

A number of other institutional investors also recently made changes to their positions in SION. Eventide Asset Management LLC acquired a new position in shares of Sionna Therapeutics in the fourth quarter valued at approximately $26,290,000. Vanguard Group Inc. lifted its holdings in Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the last quarter. State Street Corp lifted its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the last quarter. Jennison Associates LLC boosted its stake in Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares during the period. Finally, Viking Global Investors LP boosted its stake in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wedbush cut Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a research report on Monday, August 10th. JonesTrading cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Citizens Jmp downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th. Guggenheim lowered shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 10th. Finally, BTIG Research cut shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Sionna Therapeutics has a consensus rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION opened at $6.46 on Friday. The company has a market capitalization of $292.07 million, a P/E ratio of -2.96 and a beta of 1.33. Sionna Therapeutics, Inc. has a 1 year low of $4.01 and a 1 year high of $54.97. The business’s 50 day simple moving average is $39.18 and its 200 day simple moving average is $39.18.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, sell-side analysts anticipate that Sionna Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 85,918 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is currently owned by insiders.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.